Orthostatic Blood Pressure Test for Risk Stratification in XXXX with @entity1121 .

@entity1164 @entity1 @entity1479 @entity1165 @entity1162 @entity1163 @entity2357 @entity20833 @entity1121
BACKGROUND: @entity1121 ( @entity1121 ) is the most common cause of @entity1164 ( @entity1164 ) in young adults, mainly ascribed to @entity1165 ( @entity1165 ). Assuming that @entity1165 is the major cause of (pre-) @entity1163 in @entity1121 @entity1 , its occurrence is essential for @entity1164 risk stratification and primarily preventive @entity1479 . However, evidence of @entity1165 during @entity1163 is often missing. As the differentiation of potential lethal causes for @entity1163 such as @entity1165 from more harmless reasons is crucial, @entity1121 @entity1 were screened for @entity20833 by using a simple orthostatic blood pressure test. METHODS: Over 15 months (IQR [9;20]) 100 @entity1121 @entity1 (55.8  16.2 yrs, 61% male) were evaluated for (pre-) @entity1163 and @entity1165 (24h-ECGs, device-memories) within the last five years. Eighty @entity1 underwent an orthostatic blood pressure test. @entity2357 models were used for statistical analysis. RESULTS: In older @entity1 (>40 yrs) a positive orthostatic test result increased the chance of (pre-) @entity1163 by a factor of 63 (95%-CI [8.8; 447.9], p<0.001; 93% sensitivity, 95%-CI [76; 99]; 74% specificity, 95%-CI [58; 86]). No correlation with @entity1165 was shown. A @entity1162 also increased the chance of (pre-) @entity1163 by a factor of 6.6 (95%-CI [2.0; 21.7]; p=0.002). CONCLUSIONS: The orthostatic blood pressure test is highly valuable for evaluation of @entity1163 and @entity1163 especially in older @entity1121 @entity1 , suggesting that @entity1163 might be more relevant than previously assumed. Considering the high complication rates due to @entity1479 therapies, this test may provide useful information for the evaluation of @entity1163 in individual risk stratification and may help to prevent unnecessary device implantations, especially in older @entity1121 @entity1 .
